信必可都保和舒利迭治疗支气管哮喘的疗效对比  

The Comparison of Effect of Symbicort Turbuhaler and Seretide in the Treatment of Patients with Bronchial Asthma

作　　者：罗虹[1] 

机构地区：[1]四川省人民医院保健科,成都610072

出　　处：《中西医结合研究》2010年第1期11-14,共4页Research of Integrated Traditional Chinese and Western Medicine

摘　　要：目的评价信必可都保和舒利迭在治疗轻、中度支气管哮喘的临床疗效及安全性,并对二者的疗效加以比较。方法将80例支气管哮喘患者随机分为信必可都保组和舒利迭组,比较两组治疗前后的临床疗效和肺功能。结果经治疗两组患者的哮喘症状均得到改善,但信必可都保组症状改善更显著(P<0.05);在肺功能方面,两组患者第1秒用力呼气量(FEV1)都有所提高,两组间比较差异无统计学意义,但信必可都保组对晨间呼气峰流速(PEF)提高较舒利迭组显著(P<0.05),两组不良事件的发生率无差异(P>0.05)。结论信必可都保和舒利迭对支气管哮喘的症状和肺功能都有良好的改善作用,但信必可都保起效时间更快。Objective To evaluat treatment of patients with was conducted to compare bronchial a the clinical e the effect and safety between Symbicort Turbuhaler and Seretide in the sthma and compare the curative effect. Methods Trabant comparative study effect and safety of Symbicort Turbuhaler and Seretide in the treatment of 80 patients with bronchial asthma, 40 patients received Symbicort Turbuhaler and the others received Seretide, the clinical symptoms, lung function and adverse events were observed. Results Improvement in asthma symptoms were observed in the two groups,improvement in Symbicort Turbuhaler group was earlier than the Seretide group （P〈0.05）. Both groups got improvement in forced expiratory volume in 1 s（FEV1）, and there was no difference in two grotlps. Symbicort Turbuhaler made rapid improvement in morning peak expiratory flow（PEF）compared with the Seretide group（P〈0.05）. The two groups were similar in terms of advers events（P〉0.05）. Conclusion Symbicort Turbuhaler and Seretide have good efficacy and safety,but Symbicort Turbuhaler had more rapid improvement than Seretide.

关 键 词：信必可都保 舒利迭 支气管哮喘 肺功能 疗效 

分 类 号：R562.25[医药卫生—呼吸系统]